Breaking News Instant updates and real-time market news.

2020-05-01 11:13:09 AEM Agnico Eagle $59.08 / +0.35 (+0.60%) 11:13 05/01/20 05/01 11:13 05/01/20 11:13	Agnico Eagle price target raised to C$60 from C$54 at BMO Capital BMO Capital analyst Jackie Przybylowski raised the firm's price target on Agnico Eagle to C$60 from C$54 and keeps an Outperform rating on the shares.	01 May
AEM Agnico Eagle $59.08 / +0.35 (+0.60%) 05/01/20 CIBC CIBC backs Outperformer on Agnico Eagle after 'solid' Q1 results 05/01/20 RBC Capital Agnico Eagle's Q1 results mixed relative to expectations, says RBC Capital 03/24/20 TD Securities Agnico Eagle upgraded to Buy from Hold at TD Securities 03/02/20 Canaccord Agnico Eagle upgraded to Buy from Hold at Canaccord

2020-05-01 11:13:09

AEM

Agnico Eagle

$59.08 / +0.35 (+0.60%)

11:13

05/01/20

05/01

11:13

05/01/20

11:13

Agnico Eagle price target raised to C$60 from C$54 at BMO Capital

BMO Capital analyst Jackie Przybylowski raised the firm's price target on Agnico Eagle to C$60 from C$54 and keeps an Outperform rating on the shares.

01
May

AEM Agnico Eagle

$59.08 / +0.35 (+0.60%)

05/01/20 CIBC: CIBC backs Outperformer on Agnico Eagle after 'solid' Q1 results

05/01/20 RBC Capital: Agnico Eagle's Q1 results mixed relative to expectations, says RBC Capital

03/24/20 TD Securities: Agnico Eagle upgraded to Buy from Hold at TD Securities

03/02/20 Canaccord: Agnico Eagle upgraded to Buy from Hold at Canaccord

TODAY'S FREE FLY STORIES

Options	Bristol Myers Squibb call volume above normal and directionally bullish » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 10:03 Today Bristol-Myers says Phase 3 trials of deucravacitinib met co-primary endpoints 06:54 Today Bristol-Myers announces EMA's CHMP recommends approval of Onureg in Europe 06:47 Today Bristol-Myers announces EMA's CHMP recommends approval of Opdivo 04/16/21 Bristol-Myers confirms FDA approves Opdivo combo for gastric cancer BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/21/21 Citi Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data 04/21/21 Citi Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy 04/13/21 Truist Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility 04/13/21 Truist Bristol-Myers upgraded to Buy from Hold at Truist BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/01/21 Accidental disclosure show Bristol-Myers, I.R.S. $1B tax fight, NY Times reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/13/21 FedEx, Booking Holdings upgrades among today's top calls on Wall Street 03/29/21 Fly Intel: Pre-market Movers 02/09/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks 11:00 Today Pharmaceuticals 12:00 Today Biotechnology 04/29/21 Bristol-Myers - BMY 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 05/20/21 PDUFA Date for CM-577 - Opdivo 05/25/21 PDUFA Date for CM-649 Opdivo+ Yervoy or Chemo 05/30/21 PDUFA Date for Zeposia (Ozanimod) 01/28/22 PDUFA Date for Mavacamten 05/04/21 Bristol Myers Squibb Co BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/07/21 Unusually active option classes on open April 7th 01/20/21 Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish
Conference/Events	Cowen pharmaceuticals analysts to hold analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) Pharmaceuticals Analysts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 10:03 Today Bristol-Myers says Phase 3 trials of deucravacitinib met co-primary endpoints 06:54 Today Bristol-Myers announces EMA's CHMP recommends approval of Onureg in Europe 06:47 Today Bristol-Myers announces EMA's CHMP recommends approval of Opdivo 04/16/21 Bristol-Myers confirms FDA approves Opdivo combo for gastric cancer BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/21/21 Citi Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data 04/21/21 Citi Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy 04/13/21 Truist Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility 04/13/21 Truist Bristol-Myers upgraded to Buy from Hold at Truist BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/01/21 Accidental disclosure show Bristol-Myers, I.R.S. $1B tax fight, NY Times reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/13/21 FedEx, Booking Holdings upgrades among today's top calls on Wall Street 03/29/21 Fly Intel: Pre-market Movers 02/09/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks 11:00 Today Pharmaceuticals 12:00 Today Biotechnology 04/29/21 Bristol-Myers - BMY 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 05/20/21 PDUFA Date for CM-577 - Opdivo 05/25/21 PDUFA Date for CM-649 Opdivo+ Yervoy or Chemo 05/30/21 PDUFA Date for Zeposia (Ozanimod) 01/28/22 PDUFA Date for Mavacamten 05/04/21 Bristol Myers Squibb Co BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/07/21 Unusually active option classes on open April 7th 01/20/21 Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish
Conference/Events	Cantor Fitzgerald biopharma analysts hold an analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Large Cap & Biopharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	UBS technology analyst to hold an analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Technology Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	Truist digital advertising analysts to hold analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Digital Ad Analysts,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Hot Stocks	Allegiance Bancshares approves stock repurchase authorization up to 1M shares » 10:24 04/23/21 04/23 10:24 04/23/21 10:24 ABTX Allegiance Bancshares $39.02 / + (+0.00%) On April 22, 2021, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10:23 Today Allegiance Bancshares appoints Raimundo Riojas to board of directors 01/28/21 Allegiance Bancshares raises quarterly dividend 20% to 12c per share ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10/02/20 Janney Montgomery Scott Allegiance Bancshares initiated with a Neutral at Janney Montgomery Scott ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares reports Q4 EPS 77c, consensus 71c 10/29/20 Allegiance Bancshares reports Q3 EPS 79c, consensus 52c 04/29/21 Allegiance Bancshares - ABTX
Recommendations	WeCommerce price target lowered to C$23 from C$26 at TD Securities » 10:23 04/23/21 04/23 10:23 04/23/21 10:23 WECMF WeCommerce $14.79 / +0.4312 (+3.00%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Allegiance Bancshares appoints Raimundo Riojas to board of directors » 10:23 04/23/21 04/23 10:23 04/23/21 10:23 ABTX Allegiance Bancshares $39.02 / + (+0.00%) Allegiance Bancshares… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares raises quarterly dividend 20% to 12c per share ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10/02/20 Janney Montgomery Scott Allegiance Bancshares initiated with a Neutral at Janney Montgomery Scott ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares reports Q4 EPS 77c, consensus 71c 10/29/20 Allegiance Bancshares reports Q3 EPS 79c, consensus 52c 04/29/21 Allegiance Bancshares - ABTX
Recommendations	Intact Financial price target raised to C$185 from C$175 at TD Securities » 10:22 04/23/21 04/23 10:22 04/23/21 10:22 IFCZF Intact Financial $130.32 / -0.03 (-0.02%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IFCZF Intact Financial $130.32 / -0.03 (-0.02%) 02/12/21 Desjardins Intact Financial price target raised to C$175 from C$170 at Desjardins 02/10/21 National Bank Intact Financial price target raised to C$200 from C$192 at National Bank 02/10/21 TD Securities Intact Financial price target raised to C$175 from C$170 at TD Securities 12/08/20 Scotiabank Intact Financial price target raised to C$175 from C$166 at Scotiabank
Hot Stocks	GlaxoSmithKline reports European Commission approves Jemperli » 10:22 04/23/21 04/23 10:22 04/23/21 10:22 GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) GlaxoSmithKline announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 06:41 Today Roche announces FDA approval of VENTANA MMR RxDx panel 04/22/21 GlaxoSmithKline announces FDA approval of JEMPERLI 04/22/21 FDA approves Jemperli for dMMR endometrial cancer 04/22/21 GlaxoSmithKline confirms FDA approval for Jemperli GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/20/21 Morgan Stanley GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley 04/20/21 UBS GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS 04/20/21 Citi GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi 03/23/21 Fly Intel: Top five analyst downgrades GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/15/21 Activist Elliott builds 'multibillion-pound' stake in GlaxoSmithKline, FT says 02/09/21 Teva wins new hearing on $235M GSK patent verdict, Bloomberg reports 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 03/11/21 Fly Intel: Wall Street's top stories for Thursday 03/11/21 Fly Intel: Wall Street's top stories at midday 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 05/24/21 Global Healthcare Virtual Conference 2021 04/28/21 GlaxoSmithKline - GSK GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/15/21 Unusually active option classes on open April 15th

Recommendations	Walmart+ members may have declined to 11.1M in March, says Cowen » 10:21 04/23/21 04/23 10:21 04/23/21 10:21 WMT Walmart $139.75 / +0.08 (+0.06%) Cowen analyst Oliver Chen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WMT Walmart $139.75 / +0.08 (+0.06%) 04/20/21 Velodyne Lidar signs multi-year sales agreement with Gatik 04/20/21 U.K.'s CMA: Bellis' purchase of Asda raises some competition concerns 04/19/21 Walmart adds the BinaxNOW COVID-19 Antigen Self Test 04/19/21 Abbott begins shipping BinaxNOW COVID-19 Ag Self Test to retailers WMT Walmart $139.75 / +0.08 (+0.06%) 04/06/21 Morgan Stanley Walmart+ membership 'seems to have stagnated,' says Morgan Stanley 03/16/21 MKM Partners Walmart price target lowered to $141 from $154 at MKM Partners 02/23/21 Evercore ISI Walmart accelerating change with investments, says Evercore ISI 02/19/21 Morgan Stanley Walmart terminal value rising with investments, says Morgan Stanley WMT Walmart $139.75 / +0.08 (+0.06%) 02/18/21 Walmart reports Q4 adjusted EPS $1.39, consensus $1.51 02/17/21 Notable companies reporting before tomorrow's open 02/17/21 Notable companies reporting before tomorrow's open 11/17/20 Walmart reports Q3 adjusted EPS $1.34, consensus $1.18 WMT Walmart $139.75 / +0.08 (+0.06%) 04/21/21 Walmart phasing out automated pickup towers, WSJ reports 04/13/21 Walmart compliance chief leaving company, WSJ reports 04/13/21 Walmart chief ethics and compliance officer leaving company, WSJ says 04/09/21 McDonald's closing 'hundreds' of restaurants inside Walmart, WSJ reports WMT Walmart $139.75 / +0.08 (+0.06%) 04/19/21 Charged: Walmart invests in GM-backed self-driving company Cruise 04/19/21 Vizio rises as Wall Street analysts roll out bullish coverage 03/17/21 Street Fight: Analysts diverge on Plug following financial restatement news 03/10/21 Fly Intel: What to watch in Oracle's earnings report 06/02/21 Wal-Mart Stores, Inc. WMT Walmart $139.75 / +0.08 (+0.06%) 04/20/21 Wal-Mart call volume above normal and directionally bullish 04/06/21 Wal-Mart call volume above normal and directionally bullish 04/05/21 Unusually active option classes on open April 5th 03/29/21 Unusually active option classes on open March 29th
Recommendations	Well Health Technologies price target raised to C$10.50 from C$10 at TD Securities » 10:19 04/23/21 04/23 10:19 04/23/21 10:19 WLYYF Well Health Technologies $5.50 / -0.1591 (-2.81%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research WLYYF Well Health Technologies $5.50 / -0.1591 (-2.81%) 03/19/21 TD Securities Well Health price target lowered to C$10 from C$11 at TD Securities 03/10/21 Desjardins Well Health Technologies upgraded to Buy from Hold at Desjardins 02/18/21 Stifel Well Health Technologies price target raised to C$13.50 from C$10 at Stifel 02/10/21 Desjardins Well Health Technologies downgraded to Hold from Buy at Desjardins
Recommendations	Superior Plus price target raised to C$16.50 from C$15.50 at TD Securities » 10:19 04/23/21 04/23 10:19 04/23/21 10:19 SUUIF Superior Plus $11.79 / -0.0109 (-0.09%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SUUIF Superior Plus $11.79 / -0.0109 (-0.09%) 05:00 Today Industrial Alliance Superior Plus downgraded to Hold from Buy at Industrial Alliance 02/22/21 BMO Capital Superior Plus price target raised to C$12.50 from C$12 at BMO Capital 02/19/21 TD Securities Superior Plus price target raised to C$15.50 from C$14.50 at TD Securities 02/19/21 Scotiabank Superior Plus price target raised to C$15 from C$13 at Scotiabank
Technical Analysis	NASDAQ market internals summary » 10:17 04/23/21 04/23 10:17 04/23/21 10:17 $NSD NASDAQ Market Internals / + Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Technical Analysis $NSD NASDAQ Market Internals / + 04/22/21 NASDAQ market internals summary 04/22/21 NASDAQ market internals summary 04/22/21 NASDAQ market internals summary 04/22/21 NASDAQ market internals summary
Technical Analysis	NYSE market internals summary » 10:16 04/23/21 04/23 10:16 04/23/21 10:16 $NYE NYSE Market Internals / + Volume is average for… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals / + 04/22/21 NYSE market internals summary 04/22/21 NYSE market internals summary 04/22/21 NYSE market internals summary 04/22/21 NYSE market internals summary

Hot Stocks	Sanofi announces presentation of Dupixent analyses on safety, efficacy » 10:15 04/23/21 04/23 10:15 04/23/21 10:15 SNY Sanofi $51.48 / -0.57 (-1.10%) New analyses from… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events SNY Sanofi $51.48 / -0.57 (-1.10%) 10:04 Today Regeneron announces new analyses on Dupixent in patients with Atopic Dermatitis 04/22/21 MediciNova receives two milestone payments from Sanofi subsidiary for $4M 04/20/21 Kazia Therapeutics expands pipeline to include EVT801 04/19/21 Sanofi says EC approves second indication of Sarclisa for relapsed MM SNY Sanofi $51.48 / -0.57 (-1.10%) 04/06/21 Barclays Sanofi price target raised to EUR 85 from EUR 80 at Barclays 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day SNY Sanofi $51.48 / -0.57 (-1.10%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year SNY Sanofi $51.48 / -0.57 (-1.10%) 03/15/21 BioNTech recruits Novartis, Sanofi to boost vaccine production, WSJ reports 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports SNY Sanofi $51.48 / -0.57 (-1.10%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 04/28/21 Sanofi - SNY 05/18/21 PDUFA Date for Avalglucosidase Alfa
General news	FX Action: The dollar » 10:15 04/23/21 04/23 10:15 04/23/21 10:15 $ECON Economic Data / + FX Action: The dollar was… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><<
General news	U.S. new home sales surged 20.7% to 1,021k in March » 10:15 04/23/21 04/23 10:15 04/23/21 10:15 $ECON Economic Data / + U.S. new home sales… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><<
General news	Treasury Action: yields have jumped up » 10:15 04/23/21 04/23 10:15 04/23/21 10:15 $ECON Economic Data / + Treasury Action: yields… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><<
Hot Stocks	Arena Pharmaceuticals: Etrasimod 2mg group achieved SS in Phase 2b trial » 10:11 04/23/21 04/23 10:11 04/23/21 10:11 ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) Arena Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) 03/02/21 Arena Pharmaceuticals slides after IBS trial did not meet primary endpoint 03/02/21 Arena Pharmaceuticals reports topline results from Phase 2b CAPTIVATE trial 02/02/21 Arena Pharmaceuticals completes enrollment of ELEVATE UC 52 trial 12/08/20 Arena Pharmaceuticals achieves target enrollment for Phase 3 ELEVATE UC 52 trial ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) 04/06/21 Evercore ISI Evercore starts 'compelling' Arena spinoff Longboard at Outperform 03/26/21 H.C. Wainwright Arena Pharmaceuticals price target raised to $120 from $90 at H.C. Wainwright 03/03/21 Cantor Fitzgerald Arena Pharmaceuticals price target lowered to $100 from $106 at Cantor Fitzgerald 03/03/21 JonesTrading Arena Pharmaceuticals price target lowered to $94 from $101 at JonesTrading ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) 02/23/21 Arena Pharmaceuticals reports Q4 EPS ($2.10), consensus ($1.85) 11/09/20 Arena Pharmaceuticals reports Q3 EPS ($1.69), consensus ($1.87) 28 May ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) 11/05/20 Governor Cuomo says NY 'ripe' for pot legalization, amNewYork says 11/04/20 Marijuana legalization measures set to pass in five states, Tech Crunch says ARNA Arena Pharmaceuticals $67.71 / +0.91 (+1.36%) 03/02/21 Fly Intel: After-Hours Movers 11/10/20 Fly Intel: Wall Street's top stories for Tuesday 11/10/20 Fly Intel: Wall Street's top stories at midday 11/10/20 Fly Intel: Pre-market Movers

Hot Stocks	Navigator Holdings awarded four handysize timecharter contracts » 10:11 04/23/21 04/23 10:11 04/23/21 10:11 NVGS Navigator Holdings $9.54 / + (+0.00%) Navigator Holdings… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVGS Navigator Holdings $9.54 / + (+0.00%) 04/12/21 Navigator Holdings, Ultragas ApS to merge fleets, businesses 04/12/21 Navigator Holdings, Ultragas ApS to merge fleets, businesses 12/29/20 Navigator Holdings closes sale of 39.1% equity interest to BW Group 12/15/20 WL Ross & Co. to sell 39.1% interest in Navigator Holdings to BW Group NVGS Navigator Holdings $9.54 / + (+0.00%) 01/29/21 Jefferies Navigator Holdings price target raised to $14 from $12 at Jefferies 01/27/21 Evercore ISI Navigator Holdings downgraded to In Line from Outperform at Evercore ISI 01/27/21 Evercore ISI Navigator Holdings downgraded to In Line from Outperform at Evercore ISI NVGS Navigator Holdings $9.54 / + (+0.00%) 03/18/21 Navigator Holdings reports Q4 preliminary EPS 6c, two estimates 15c 11/12/20 Navigator Holdings reports Q3 EPS 3c, consensus 9c
Hot Stocks	Incyte, Lilly announce new analyses of BREEZE-AD5 Phase 3 clinical trial data » 10:10 04/23/21 04/23 10:10 04/23/21 10:10 INCY Incyte $84.30 / +0.12 (+0.14%) , LLY Eli Lilly $187.92 / +0.88 (+0.47%) Through new analyses of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 10:01 Today Incyte announces new findings from pooled analyses of Phase 3 TRuE-AD program 04/20/21 Eli Lilly, Incyte announce results from BRAVE-AA1 trial 04/08/21 Eli Lilly, Incyte announce baricitinib study did not meet primary endpoint 04/06/21 Eli Lilly, Incyte announce FDA extension of baricitinib sNDA review period LLY Eli Lilly $187.92 / +0.88 (+0.47%) 10:08 Today Eli Lilly reports on clinical trial meta-analysis of Taltz 04/20/21 Eli Lilly, Incyte announce results from BRAVE-AA1 trial 04/16/21 FDA revokes emergency use authorization for Eli Lilly's bamlanivimab 04/16/21 Eli Lilly requests FDA revoke EUA for bamlanivimab 700 mg alone INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 02/10/21 SVB Leerink Incyte downgraded to Market Perform from Outperform at SVB Leerink 01/07/21 Truist Incyte initiated with a Buy at Truist 01/07/21 Truist Incyte initiated with a Buy at Truist 01/04/21 Guggenheim Incyte upgraded to Buy from Neutral at Guggenheim LLY Eli Lilly $187.92 / +0.88 (+0.47%) 04/12/21 Benchmark Benchmark sees full FDA approval of Regeneron's REGEN-COV coming 04/06/21 JPMorgan JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug 03/24/21 BMO Capital AbCellera price target lowered to $59 from $61 at BMO Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 02/09/21 Incyte reports Q4 EPS 93c, consensus 75c 02/08/21 Notable companies reporting before tomorrow's open 02/08/21 Notable companies reporting before tomorrow's open 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c LLY Eli Lilly $187.92 / +0.88 (+0.47%) 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/28/21 Notable companies reporting before tomorrow's open INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 04/07/21 Concert higher after Insightia says Incyte settlement may be close LLY Eli Lilly $187.92 / +0.88 (+0.47%) 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 02/09/21 Fly Intel: Pre-market Movers LLY Eli Lilly $187.92 / +0.88 (+0.47%) 03/15/21 Fly Intel: Wall Street's top stories for Monday 03/15/21 Fly Intel: Wall Street's top stories at midday 03/15/21 Fly Intel: Pre-market Movers 03/10/21 Fly Intel: Wall Street's top stories for Wednesday 05/24/21 Global Healthcare Virtual Conference 2021 04/27/21 Eli Lilly - LLY 05/04/21 Incyte - INCY 06/21/21 PDUFA Date for Ruxolitinib Cream 06/22/21 PDUFA Date for Jakafi (ruxolitinib) sNDA for GVHD 07/25/21 PDUFA Date for Retifanlimab 05/03/21 Eli Lilly & Co. 05/06/21 Eli Lilly 05/26/21 Incyte Corporation INCY LLY INCY Incyte $84.30 / +0.12 (+0.14%) 01/22/21 Early notable gainers among liquid option names on January 22nd 12/14/20 Early notable gainers among liquid option names on December 14th LLY Eli Lilly $187.92 / +0.88 (+0.47%) 03/11/21 Eli Lilly call volume above normal and directionally bullish 03/10/21 Eli Lilly call volume above normal and directionally bullish 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th
Hot Stocks	Arcutis Biotherapeutics presents roflumilast safety, efficacy data » 10:09 04/23/21 04/23 10:09 04/23/21 10:09 ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) Arcutis Biotherapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) 04/19/21 Arcutis Biotherapeutics to present new roflumilast data at AAD virtual meeting 04/12/21 Arcutis Biotherapeutics initiates Phase 3 trial of topical roflumilast cream 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/18/21 Arcutis Biotherapeutics enrolls first patient in Phase 2a trial of ARQ-252 ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) 02/02/21 Truist Arcutis Biotherapeutics price target raised to $48 from $38 at Truist 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) 02/16/21 Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) 03 Feb 02 Oct ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) 02/16/21 Fly Insider: Power REIT, Amphastar among week's notable insider trades 02/01/21 Fly Intel: After-Hours Movers ARQT Arcutis Biotherapeutics $30.58 / -0.34 (-1.10%) 01/21/21 Eighteen new option listings and one option delisting on January 21st
Hot Stocks	Eli Lilly reports on clinical trial meta-analysis of Taltz » 10:08 04/23/21 04/23 10:08 04/23/21 10:08 LLY Eli Lilly $188.00 / +0.96 (+0.51%) Eli Lilly reports that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LLY Eli Lilly $188.00 / +0.96 (+0.51%) 04/20/21 Eli Lilly, Incyte announce results from BRAVE-AA1 trial 04/16/21 FDA revokes emergency use authorization for Eli Lilly's bamlanivimab 04/16/21 Eli Lilly requests FDA revoke EUA for bamlanivimab 700 mg alone 04/13/21 Eli Lilly announces Diogo Rau as chief information, digital officer LLY Eli Lilly $188.00 / +0.96 (+0.51%) 04/12/21 Benchmark Benchmark sees full FDA approval of Regeneron's REGEN-COV coming 04/06/21 JPMorgan JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug 03/24/21 BMO Capital AbCellera price target lowered to $59 from $61 at BMO Capital 03/17/21 Mizuho AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho LLY Eli Lilly $188.00 / +0.96 (+0.51%) 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/28/21 Notable companies reporting before tomorrow's open LLY Eli Lilly $188.00 / +0.96 (+0.51%) 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says LLY Eli Lilly $188.00 / +0.96 (+0.51%) 03/15/21 Fly Intel: Wall Street's top stories for Monday 03/15/21 Fly Intel: Wall Street's top stories at midday 03/15/21 Fly Intel: Pre-market Movers 03/10/21 Fly Intel: Wall Street's top stories for Wednesday 05/24/21 Global Healthcare Virtual Conference 2021 04/27/21 Eli Lilly - LLY 05/03/21 Eli Lilly & Co. 05/06/21 Eli Lilly LLY Eli Lilly $188.00 / +0.96 (+0.51%) 03/11/21 Eli Lilly call volume above normal and directionally bullish 03/10/21 Eli Lilly call volume above normal and directionally bullish 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th
Hot Stocks	Brickell Biotech reports results from ARGYLE phase 3 study » 10:07 04/23/21 04/23 10:07 04/23/21 10:07 BBI Brickell Biotech / + Brickell Biotech… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate BBI Brickell Biotech / + 04/15/21 Brickell Biotech announces publication of HDSM-Ax scale validation results 03/05/21 Brickell Biotech to host KOL webinar on the hyperhidrosis market 01/19/21 Brickell announces Japan Phase 3 study results for sofpironium bromide gel 12/07/20 Brickell Biotech doses first patient in second U.S. Phase 3 study BBI Brickell Biotech / + 09/25/20 Lake Street Approval in Japan validating for Brickell Biotech, says Lake Street 08/28/20 Lake Street Brickell Biotech initiated with a Buy at Lake Street 08/25/20 Oppenheimer Brickell Biotech initiated with an Outperform at Oppenheimer 23 Oct 18 Jun

Events

Earnings calls, analyst events, roadshows and more

INDB
Today at 10:30

Independent Bank - INDB Conference Calls
GBCI
Today at 11:00

Glacier Bancorp - GBCI Conference Calls
OZK
Today at 11:00

Bank OZK - OZK Conference Calls
AZZ
Today at 11:00

AZZ Inc. - AZZ Conference Calls
EIG
Today at 11:00

Employers Holdings - EIG Conference Calls
NBHC
Today at 11:00

National Bank - NBHC Conference Calls
NGA
Today at 11:00

NORTHERN GENESIS ACQUISITION Firm Sponsored Meetings
SNCA
Today at 11:00

Seneca Biopharma Inc Firm Sponsored Meetings
Today at 11:00

Digital Advertising Industry Meetings
Today at 11:00

Biopharma & Medical Devices Industry Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	CHWY X CHWY Chewy Block Trade Managers: Morgan Stanley Priced at: $82.50 6.1M Shares IFBD X IFBD Infobird IPO Managers: WestPark Capital Priced at: $4.00 6.25M Shares
Tues	DV X DV DoubleVerify IPO Managers: Goldman Sachs & JPMorgan, Barclays, RBC Capital, Truist, William Blair, KeyBanc, Canaccord, JMP Securities, Needham, Loop Capital, Capital One Priced at: $27.00 13.3M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PATH X PATH UiPath IPO Managers: Morgan Stanley & JPMorgan, BofA, Credit Suisse, Barclays, Wells Fargo, SMBC Nikko, BMO Capital, MIZU, KeyBanc, TD Securities, Truist, Cowen, Evercore ISI, Macquarie, Nomura, RBC Capital, Canaccord, DA Davidson, Oppenheimer, Needham Priced at: $56.00 23.89M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SKYT X SKYT SkyWater Technology IPO Managers: Jefferies & Cowen, Piper Sandler Priced at: $14.00 6.96M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TRKA X TRKA Troika Media IPO Managers: Kingswood Priced at: $4.15 5.78M Shares FUTU X FUTU Futu Holdings Secondary Managers: BofA & Haitong Priced at: $130.00 9.5M Shares ZLAB X ZLAB Zai Lab Secondary Managers: JPMorgan, Goldman Sachs, Jefferies, Citi, SVB Leerink & Guggenheim Priced at: $150.00 4.78M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NOTV X NOTV Inotiv Spot Secondary Managers: Colliers Priced at: $17.00 2.647M Shares
Wed	KNBE X KNBE KnowBe4 IPO Managers: Morgan Stanley, Goldman Sachs, BofA & KKR Priced at: $16.00 9.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NPCE X NPCE NeuroPace IPO Managers: JPMorgan & Morgan Stanley, Wells Fargo, SVB Leerink Priced at: $17.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ZY X ZY Zymergen IPO Managers: JPMorgan & Goldman Sachs, BofA, UBS, LAZA Priced at: $31.00 16.13M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EOLS X EOLS Evolus Spot Secondary Managers: SVB Leerink, Stifel & Cantor Fitzgerald Priced at: $9.50 9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NBSE X NBSE NeuBase Therapeutics Spot Secondary Managers: RBC Capital, Oppenheimer & Chardan, National Securities Priced at: $5.00 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	AGTI X AGTI Agiliti IPO Managers: BofA, Goldman Sachs, Morgan Stanley & BMO Capital, Citi, JEFF< UBSW, KeyBanc, Raymond James, MUFG, SMBC Nikko, MISC, SIEB Priced at: $14.00 26.316M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial IMPL X IMPL Impel NeuroPharma IPO Managers: Cowen & Guggenheim, Wedbush Priced at: $15.00 5.33M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RAIN X RAIN Rain Therapeutics IPO Managers: Goldman Sachs, Citi, Piper Sandler & Guggenheim Priced at: $17.00 7.353M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SWIM X SWIM Latham Group IPO Managers: Barclays, BofA, Morgan Stanley & Goldman Sachs, Nomura, William Blair, Baird, KeyBanc, Truist Priced at: $19.00 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TMCI X TMCI Treace Medical IPO Managers: JPMorgan & Morgan Stanley, SVB Leerink, Stifel Priced at: $17.00 11.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDAP X EDAP EDAP TMS Spot Secondary Managers: Piper Sandler Priced at: $6.75 4.15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Agnico Eagle price target raised to C$60 from C$54 at BMO Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access